

Glenmark Pharmaceuticals Announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD

In a global first, Glenmark introduces the only known nebulized fixed-dose combination of Glycopyrronium, Formoterol, and Budesonide

Mumbai, India, 25 November 2025: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led global pharmaceutical company, today announced the launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world's first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI).

Commenting on the launch, **Mr. Alok Malik, President & Business Head, India Formulations, Glenmark Pharmaceuticals** said, *"At Glenmark, innovation is about reimagining and redefining how therapies reach patients. With Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, the world's first nebulized triple therapy for COPD, we are transforming respiratory care. This milestone reinforces Glenmark's position as a front-runner in respiratory innovation and our commitment to making advanced, affordable, and accessible solutions for patients."*

In a clinical study conducted in India, this nebulized triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients. The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD.

Dr. Monika Tandon, Global Head of Clinical Development, Glenmark Pharmaceuticals, said, *"This launch represents a significant advancement in the management of COPD and demonstrates our focus in strengthening global respiratory leadership. Nebulizer medications are easy to use in patients with COPD. The strong efficacy and safety demonstrated in the clinical study further support this novel treatment approach in COPD."*

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)

For more information, please contact

Aakanksha Pilay | aakanksha.pilay@glenmarkpharma.com | +91 72181 71062
Akhila Natarajan | akhila.natarajan@glenmarkpharma.com | +91 98216 89525

Adfactors PR | glenmark@adfactorspr.com | +91 88502 91322